Every material Form 8-K Frazier Life Sciences Acquisition Corp. II has filed with the SEC since October 15, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Frazier Life Sciences Acquisition Corp. II, a Cayman Islands blank check company, closed its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share on October 15, 2026, for gross proceeds of $75 million. The full $75 million was placed in a U.S. trust account, and the company said it has not selected a business combination target, so shareholders' funds remain in the trust until a deal is completed or the company liquidates.
IPO: 7,500,000 Class A ordinary shares at $10.00 per share, gross proceeds of $75,000,000, closed October 15, 2026
Private placement: 300,000 Class A ordinary shares to the sponsor for gross proceeds of $3,000,000
Trust account: $75,000,000 held with Continental Stock Transfer & Trust Company as trustee
Balance sheet as of October 15, 2026 showed cash of $1,762,481 and a $3,000,000 deferred underwriting fee payable
Frazier Life Sciences Acquisition Corp. II, a special purpose acquisition company, closed its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share on October 15, 2026, raising $75 million in gross proceeds. The company also sold 300,000 private placement shares to its sponsor for $3 million, and $75 million of the proceeds was placed in a trust account for public shareholders, who can only access it through a business combination or redemption, with a 24-month deadline from the IPO closing.
IPO of 7,500,000 Class A ordinary shares at $10.00 per share closed October 15, 2026, for gross proceeds of $75 million; shares trade on Nasdaq Capital Market under FLSC
Sponsor Frazier Life Sciences Holdings II, LLC bought 300,000 private placement shares at $10.00 each, for $3 million
$75 million placed in trust account held by Continental Stock Transfer & Trust Company; company has 24 months from IPO closing to complete an initial business combination
Frazier Life Sciences Public Fund, L.P. committed to buy at least 2,500,000 Class A shares at $10.00 each, a minimum of $25 million, at the closing of a business combination
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Frazier Life Sciences Acquisition Corp. II filing is on SEC EDGAR ↗. 8-K briefs of other companies →